Physician profile
Amy Law
NPI 1861452054
$28,831.72
in general payments reported to CMS, 2019-2025
100 companies · $5,107 in 2025
The $5,107 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,399 · 2020: $2,836 · 2021: $3,902 · 2022: $4,511 · 2023: $4,806 · 2024: $4,271 · 2025: $5,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $13.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,169.98 |
| Education | $13.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,072.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,861.95 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $1,566.08 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Merck Sharp & Dohme LLC | $1,534.87 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $1,326.52 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,126.56 | 2019-2025 | Opdivo, Reblozyl |
| Incyte Corporation | $829.77 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Amgen INC. | $809.08 | 2019-2023 | Blincyto, Kyprolis, Lumakras |
| Celgene Corporation | $736.36 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Glaxosmithkline, LLC. | $697.71 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $687.09 | 2019-2025 | |
| Daiichi Sankyo INC. | $644.44 | 2019-2025 | Enhertu, Injectafer |
| Astellas Pharma US INC | $643.50 | 2019-2025 | Xospata, Xtandi, Padcev |
| Seagen INC. | $622.17 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $582.55 | 2019-2025 | Fruzaqla, Alunbrig, Ninlaro |
Show all 100 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.